Advanced Therapies Week 2026

Scaling the Future of Cell Therapy Manufacturing in San Diego

Cellistic is joining Advanced Therapies Week 2026, represented by Tarran Pierfelice and Holly Gills from our Business Development team.

As the cell therapy field advances, the need for scalable, GMP-compliant manufacturing of allogeneic, iPSC-derived therapies has never been greater — and Cellistic brings over 15 years of development experience to help therapeutic developers turn this promise into reality.

Supporting the Development of Cell Therapies at Scale

Bringing iPSC-based therapies to the clinic requires:

• Streamlined development from reprogramming through differentiation and expansion, with reliable gene editing strategies.
• Robust GMP-compliant manufacturing processes
• Consistent quality, reproducibility, and scalability

Our iPSC-Derived Therapy Solutions

• Pulse™ platform for Cell Line Development – accelerates and de-risks GMP Master Cell Bank (MCB) generation
• Echo™ platform for Differentiation & Manufacturing at scale – expertise across multiple cell types (T cells, macrophages, and NK cells); includes Echo™-NK, delivering 20B+ clinic-ready cells in 18 months for €3M
• STAR-CRISPR™ – Cellistic's proprietary, high-efficiency gene editing technology for multiplex edits and clear IP positioning; also available for outlicensing
• Allo Chassis™ – ready-to-use, off-the-shelf immune-cloaked iPSC lines, designed to reduce immunogenicity and accelerate early development timelines
• Comprehensive CDMO services – end-to-end support from process development to product release, including analytical development and cell banking; expert services backed by 15 years of experience to help developers move quickly from concept to clinical readiness

Let's talk about your program

Meet Tarran and Holly to explore how Cellistic’s integrated platforms, technologies and CDMO expertise can streamline the development and clinical readiness of your cell therapy product.